NeoImmuneTech, Inc.

Equities

A950220

KR8840140006

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
1,465 ^KRW	-2.92%		-5.85%	-27.65%

03/06	NeoImmuneTech's New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors in Immuno-Oncology	CI
02/04	NeoImmuneTech, Inc. Announces Chief Executive Officer Changes	CI

NeoImmuneTech, Inc. Receives U.S. FDA Clearance of IND Application for Phase 1b/2a Study of Hyleukin-7 (NT-I7) and Keytruda (Pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors

January 27, 2020 at 05:30 pm IST

NeoImmuneTech, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for the combination of NeoImmuneTech’s Hyleukin-7™ (NT-I7) and Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with relapsed/refractory (R/R) advanced solid tumors. This IND clearance allows NeoImmuneTech to initiate a Phase 1b/2a basket study evaluating this combination in patients with both checkpoint inhibitor (CPI)-treated and CPI-naïve R/R advanced solid tumors.

Latest news about NeoImmuneTech, Inc.

NeoImmuneTech's New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors in Immuno-Oncology	03/06	CI
NeoImmuneTech, Inc. Announces Chief Executive Officer Changes	02/04	CI
NeoImmuneTech, Inc. Appoints Luke Oh as President	15/01	CI
Fda Grants Orphan Drug Designation to Neoimmunetech's Nt-I7 for the Treatment of Acute Radiation Syndrome	20/11	CI
Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board	26/23/26	CI
NeoImmuneTech, Inc. to Partner with U.S. National Institute of Allergy and Infectious Diseases, National Institutes of Health for Drug Development in Acute Radiation Syndrome	03/23/03	CI
New Evidence of NeoImmuneTech's NT-I7 Clinical Efficacy in Combination with Pembrolizumab in Relapsed/Refractory (R/R) Gastrointestinal Tumors	11/22/11	CI
NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board	08/22/08	CI
NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity	15/22/15	CI
NeoImmuneTech, Inc.'s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors	06/22/06	CI
Neoimmunetech Demonstrates Nt-I7’S Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine At Aacr 2022	13/22/13	CI
NeoImmuneTech, Inc. Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers	07/22/07	CI
NeoImmuneTech, Inc. Announces the Publication of Preclinical Data Evaluating Lead Asset NT-I7	24/22/24	CI
South Korea's Secondary Stock Market Adds Largest Number of New Tech IPOs in 2021	28/21/28	MT
An unknown buyer agreed to acquire a 5.1% stake in NeoImmuneTech, Inc. from SillaJen, Inc. for KRW 10.1 billion.	25/21/25	CI
NeoImmuneTech, Inc. announced that it has received $4.7 million in funding from Hefei SPARK Venture Capital Management Co., Ltd., Kindstar Global Technology, Inc.	25/21/25	CI
NeoImmuneTech, Inc. Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting	22/21/22	CI
NeoImmuneTech, Inc. Presents Data in Three Posters At Society for Immunotherapy of Cancer Annual Meeting	16/21/16	CI
NeoimmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (Efineptakin Alfa) in Combination with PD-L1 Checkpoint Inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer	08/21/08	CI
NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma	13/21/13	CI
NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting	04/21/04	CI
NeoImmuneTech, Inc.(KOSDAQ:A950220) added to S&P Global BMI Index	20/21/20	CI
Neoimmunetech to Present At Society for Neuro-Oncology	13/21/13	CI
NeoImmuneTech, Inc. Appoints Jean Fan, M.D., as Chief Clinical Officer	25/21/25	CI
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection	26/21/26	CI

Chart NeoImmuneTech, Inc.

Duration

Period

More charts

Company Profile

NeoImmuneTech, Inc. is a clinical-stage T cell-focused biopharmaceutical company. The Company is engaged in the discovery and development of immuno-therapeutics. Its lead asset includes NT-I7 (efineptakin alfa), which is a T Cell Amplifier. NT-I7 is a human IL-7 (Interleukin-7) fusion protein that overcomes the limitations of endogenous IL-7. The IL-7 domain promotes T cell development, which plays a role in the immune response. The N-terminus of the IL-7 domain overcomes its structural instability and enables mass production of NT-I7. NT-I7 is a clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications. It is conducting multiple clinical trials of NT-I7 in multiple indications both as a monotherapy and in combination with other therapeutics, such as checkpoint inhibitors and other. Its products include NIT-106, NIT-109, NIT-110, NIT-119, NIT-120, NIT-104, NIT-107, NIT-112, NIT-105, NIT-108, NIT-113, NIT-114, NIT-115, NIT-116 and NIT-A01.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NEOIMMUNETECH, INC.	-27.65%	2.09Cr
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	13TCr
REGENERON PHARMACEUTICALS, INC.	+24.67%	12TCr
ARGENX SE	+24.98%	2.79TCr
BIONTECH SE	-17.74%	2.1TCr
GENMAB A/S	-15.20%	1.69TCr
BEIGENE, LTD.	-15.21%	1.62TCr
NEUROCRINE BIOSCIENCES, INC.	+11.91%	1.48TCr
WUXI APPTEC CO., LTD.	-47.10%	1.48TCr
SAREPTA THERAPEUTICS, INC.	+54.50%	1.41TCr

Bio Therapeutic Drugs